<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304356</url>
  </required_header>
  <id_info>
    <org_study_id>H-15601</org_study_id>
    <nct_id>NCT00304356</nct_id>
  </id_info>
  <brief_title>Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection</brief_title>
  <official_title>Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel M. Musher MD</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Medical Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is for compassionate use of nitazoxanide in the treatment of
      diarrheal disease due to Clostridium difficile infection when the patient has failed previous
      treatment with metronidazole or vancomycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clostridium difficile is the leading cause of nosocomial diarrheal disease associated with
      antibiotic therapy. This is a debilitating condition with substantial morbidity and a
      mortality that may be around 2-3%. There has been an enormous increase in this disease at the
      VA Medical Center during the past two years, just as has occurred at other hospitals
      throughout the United States.

      Currently recommended therapy for this condition is metronidazole, given orally. About 15-20%
      of patients fail to respond to initial therapy with metronidazole, and another 20% relapse
      after treatment. Relapses may be treated with another course of metronidazole; about one-half
      will respond to this therapy. The failures are treated with oral vancomycin, but this drug
      also has a failure rate of 10-20%. There is, at present, no other accepted therapy (although
      some articles in the literature favor vancomycin with ingested bacteria from benign species).
      Furthermore, there is a strong risk to the emergence of resistant bacteria when hospitalized
      patients are treated with oral vancomycin.

      Nitazoxanide is an FDA approved drug that is marketed in the U.S. and has been widely used
      throughout the world to treat parasitic diseases of the gastrointestinal tract; several
      million children have been treated with this drug during the past decade. Nitazoxanide has
      been approved as an antiprotozoal agent for oral administration in pediatric patients, ages 1
      through 11, with diarrhea. The drug acts by interfering with anaerobic metabolic pathways,
      and it has been shown to have excellent in vitro activity against C. difficile. We
      hypothesized that this drug was both safe and effective as an alternative in patients who
      have diarrheal disease caused by C. difficile. The IRB approved a double-blind protocol to
      compare metronidazole with nitazoxanide, and we have treated a total of 16 patients so far
      under this protocol.

      In our IRB-approved double blind study (by design, two thirds of the subjects have been
      randomized to the nitazoxanide), our patients have appeared to have a good response rate --
      so good, in fact, that we think that nitazoxanide may be a better drug to treat this
      infection than either metronidazole or vancomycin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nitazoxanide</measure>
    <time_frame>30 days</time_frame>
    <description>stopping of diarrhea</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Clostridium Enterocolitis</condition>
  <condition>Pseudomembranous Colitis</condition>
  <arm_group>
    <arm_group_label>active drug</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>500 mg nitazoxanide bid given to patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>500 mg bid</description>
    <arm_group_label>active drug</arm_group_label>
    <other_name>alinia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be &gt; 18 years of age

          -  Clinical diagnosis of C. difficile associated disease, based on the new onset of
             diarrhea, abdominal discomfort, or otherwise unexplained fever or leukocytosis

          -  Diagnosis of C. difficile colitis proven by positive assay for C. difficile toxin in
             feces

          -  Disease has been treated, and the symptoms failed to respond to treatment with
             metronidazole or vancomycin, or symptoms promptly relapsed after completing a course
             of therapy with either of these drugs

          -  Able to take oral medication

        Exclusion Criteria:

          -  Patients with other recognized causes of diarrhea or colitis

          -  Women of child bearing age who are pregnant, breast feeding, or not using birth
             control

          -  Patients taking coumadin, phenytoin, celecoxib, or losartan

          -  Patients with renal insufficiency (BUN or creatinine &gt;2 times baseline)

          -  Serious systemic disorder incompatible with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Musher, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine, Houston VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. Debakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2006</study_first_submitted>
  <study_first_submitted_qc>March 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <results_first_submitted>February 19, 2013</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 15, 2017</results_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VA Medical Center, Houston</investigator_affiliation>
    <investigator_full_name>Daniel M. Musher MD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Clostridium difficile Associated Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Chart review at the Houston VA for patients treated with Nitazoxanide who have failed previous therapy.</recruitment_details>
      <pre_assignment_details>This is a retrospective chart review.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nitazoxanide</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Nitazoxanide</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Nitazoxanide</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>number is 0</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nitazoxanide</title>
          <description>Patients with C. difficle who exhibit diarrhea and received nitazoxanide.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nitazoxanide</title>
        <description>stopping of diarrhea</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitazoxanide</title>
            <description>time diarrhea from C. difficile stopped.</description>
          </group>
        </group_list>
        <measure>
          <title>Nitazoxanide</title>
          <description>stopping of diarrhea</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nitazoxanide</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Musher</name_or_title>
      <organization>VA Houston</organization>
      <phone>713-794-7386</phone>
      <email>daniel.musher@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

